Margaret Meredith, APRN
Family · Amherst, NHNPI 1871902387
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,483 of the $2,887 with a category attached, or 86.0%. Regeneron accounts for 86.0% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $2,563, more than ten times the $84 reported in 2021. Among family clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $111.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2K
- AbbVie$208
- Novo Nordisk$47
- GSK$39
- Biohaven Pharmaceutical Holding Company Ltd.$33
- Pfizer$24
- plus $54 from 3 others
What the payments were for
- Travel & lodging$2,48386%
- Food & beverage$40514%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 8 | $2,483 |
| AbbVie | 9 | $208 |
| Novo Nordisk | 1 | $47 |
| GSK | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Pfizer | 1 | $24 |
| Exact Sciences | 1 | $22 |
| Shield Therapeutics Inc | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,887 in reported general payments places this provider in the 90th percentile of 713 family providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 52 | $349 |
| Duloxetine Hcl | 17 | $322 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $304 |
| Omeprazole | 12 | $303 |
| Atorvastatin Calcium | 43 | $202 |
| Allopurinol | 16 | $168 |
| Metformin Hcl | 17 | $168 |
| Rosuvastatin Calcium | 23 | $165 |
| Atenolol | 13 | $100 |
| Amlodipine Besylate | 29 | $99 |
| Simvastatin | 11 | $80 |
| Lisinopril | 20 | $73 |
| Hydrochlorothiazide | 20 | $37 |
Paid to pharmacies, not to this prescriber.
Other family in Amherst
- Wendy WrightAmherst$447K
- Tara Delle ChiaieHampton$548K
- Richard CareyNashua$51K
- Summer BellDerry$16K
- Laura HudsonDover$14K
- Debra KrisonNorth Hampton$13K
- Michelle WhiteBedford$9K
- Brant OliverConcord$9K
- Cassandra CavanaughDover$9K
- Scott SabishConcord$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.